Journal of Clinical Oncology
Articles in this Issue
A phase 1, open-label, multi-center study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors.
TPS3159 Background: Nectin-4 is a cell adhesion molecule frequently overexpressed across multiple solid tumor types, including urothelial carcinoma (UC),...
Racial and ethnic disparities in receipt of guideline concordant treatment for early-stage non-small cell lung cancer in Los Angeles County.
8068 Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality in California. Black patients experience the highest mortalit...
Adjuvant toripalimab in high-risk renal cell carcinoma after tumor resection (TUOAD-RCC): A prospective phase 2 study.
e16520 Background: Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma (RCC) improved overall survival (OS) and disease-free survival (D...
Optimizing frontline therapy for diffuse large B cell lymphoma (DLBCL) in older adults: A glofitamab-based, response-adapted, window-style study (GLORY).
TPS7094 Background: Older adults (OA) with DLBCL classified as unfit or frail based on simplified geriatric assessment (sGA) do poorly with standard doses...
Antitumor effect of PRaG therapy in a triple-negative breast cancer model.
e14604 Background: Triple-negative breast cancer (TNBC) is highly aggressive, with a high recurrence rate and poor long-term outcomes from conventional ch...
Impact of a novel oral medication delivery device on patient engagement and discontinuation in individuals receiving oral oncolytic medications.
11063 Background: Patient-reported outcomes (PROs) are essential for monitoring patient status and improving outcomes. ReX by Dosentrx physically administ...
Sex and gender influence on adverse events for melanoma patients: A comprehensive review and meta-analysis.
e21542 Background: Immunotherapy and target therapy have revolutionized melanoma treatment. However, adverse events (AEs) are still frequent and might imp...
In vitro profiling of IDRX-42 against secondary and tertiary mutations (AP/AL) found in TKI-resistant GIST.
11524 Background: The majority of Gastrointestinal Stromal Tumors (GIST) harbor a KIT mutation and respond to imatinib (IM), but over time clinical resist...
Prognostic features and intratumor microbiome in surgically resected pancreatic head, body, and tail cancer patients.
e16440 Background: This study aimed to investigate overall survival (OS) in patients with surgically resected pancreatic cancer and examined the distribut...
Site-specific analysis of treatment modalities and survival in brain metastases from neuroendocrine neoplasms: A real-world analysis.
e14006 Background: Brain metastases (BM) from neuroendocrine neoplasms (NENs) are rare and associated with poor prognosis. Limited data exists in the lite...
Outcomes with 177 lutetium-dotatate (177Lu-dotatate) in olfactory neuroblastoma (ONB): A case series.
6108 Background: Olfactory neuroblastoma (ONB) is a rare malignant tumor of the nasal cavity with a high recurrence rate after local therapy. Effective tr...
Co-expression network-based analysis of gene programs contributing to immune checkpoint inhibitor (ICI) resistance in renal cell carcinoma (RCC).
4530 Background: There is an unmet need to characterize molecular drivers of resistance to ICIs in the RCC tumor microenvironment, especially in cell-type...
Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance.
1075 Background: ET + CDK4/6i is standard-of-care for patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MB...
Use of an artificial intelligence model to predict Ki67 from H&E-stained whole slides images in breast cancer.
e13652 Background: Accurate assessment of Ki67 is critical for evaluating cellular proliferation and tumor aggressiveness in breast cancer diagnosis and p...